A Phase II Study of ZD6474 Alone and With Chemotherapy in Advanced NSCLC [non-small cell lung cancer]

Trial Profile

A Phase II Study of ZD6474 Alone and With Chemotherapy in Advanced NSCLC [non-small cell lung cancer]

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2016

At a glance

  • Drugs Vandetanib (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 30 Nov 2009 Pharmacodynamic outcomes, with respect to biomarker levels, reported in the Journal of Clinical Oncology.
    • 28 Oct 2008 Results published early online in the Journal of Clinical Oncology.
    • 20 Oct 2008 Primary endpoint 'Progression free survival' has been met at the predefined one-sided significant level of p<0.20.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top